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Abstract
Background: Tumor suppressor PTEN is known to control a variety of processes related to cell survival, proliferation, and
growth. PTEN expression is considered as a prognostic factor in some human neoplasms like breast, prostate, and thyroid
cancer.
Methodology/Principal Findings: In this study we analyzed the influence of PTEN expression on the outcome of a
randomized clinical trial of conventional versus 7-days-a-week postoperative radiotherapy for squamous cell cancer of the
head and neck. The patients with cancer of the oral cavity, oropharynx, and larynx were randomized to receive 63 Gy in
fractions of 1.8 Gy given 5 days a week (CF) or 7 days a week (p-CAIR). Out of 279 patients enrolled in the study, 147 paraffin
blocks were available for an immunohistochemical assessment of PTEN. To evaluate the prognostic value of PTEN
expression and the effect of fractionation relative to PTEN, the data on the outcome of a randomized clinical trial were
analyzed. Tumors with a high intensity of PTEN staining had significant gain in the loco-regional control (LRC) from p-CAIR
(5-year LRC 92.7% vs. 70.8%, for p-CAIR vs. CF, p=0.016, RR=0.26). By contrast, tumors with low intensity of PTEN did not
gain from p-CAIR (5-year LRC 56.2% vs. 47.2%, p=0.49, RR=0.94). The intensity of PTEN highly affected the LRC in a whole
group of 147 patients (5-year LRC 80.9% vs. 52.3% for high vs. low PTEN, p=0.0007, RR=0.32). In multivariate Cox analysis,
including neck node involvement, EGFR, nm23, Ki-67, p53, cyclin D1, tumor site and margins, PTEN remained an
independent predictor of LRC (RR=2.8 p=0.004).
Conclusions/Significance: These results suggest that PTEN may serve as a potent prognostic and predictive marker in
postoperative radiotherapy for high-risk squamous cell cancer of the head and neck.
Citation: Snietura M, Jaworska M, Mlynarczyk-Liszka J, Goraj-Zajac A, Piglowski W, et al. (2012) PTEN as a Prognostic and Predictive Marker in Postoperative
Radiotherapy for Squamous Cell Cancer of the Head and Neck. PLoS ONE 7(3): e33396. doi:10.1371/journal.pone.0033396
Editor: Torbjorn Ramqvist, Karolinska Institutet, Sweden
Received September 16, 2011; Accepted February 14, 2012; Published March 7, 2012
Copyright:  2012 Snietura et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by research grant MN 402 108 134 provided by Polish Ministry of Science and Higher Education.The funder had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mirek@snietura.net
Introduction
Tumor suppressor PTEN (Phosphatase and tensin homolog
deleted on chromosome 10) is a dual-specific phosphatase that acts
as a negative regulator of the PI3K-AKT-mTOR pathway, thus
controlling a variety of processes related to cell survival,
proliferation, and growth. PTEN performs a crucial role in the
silencing of signal transduction from membrane growth factor
receptors (EGFR, HER-2, IGFR) through the AKT signaling
cascade [1,2].
Somatic PTEN mutations and deletions or epigenetic silencing
are common in multiple tumor types, including breast, endome-
trium, and thyroid, but also tumors of central nervous system,
prostate, lung, melanoma, leukemia and lymphoma [3–11]. Loss
of PTEN can lead to tissue-specific effects, including rapid or slow
tumors, or no tumors. In many neoplasms PTEN deletion
cooperates with other genetic alternations to enhance tumorigen-
esis and may determine aggressive clinical behavior of the tumor
(e.g. anaplastic thyroid carcinomas or grade IV invasive
astrocytomas) [12].
Because the AKT pathway dictates multiple downstream
processes, including inhibition of apoptosis, tumor-cell prolifera-
tion [13], and DNA repair [14], and is also known to be associated
with radioresistance mechanisms, such as intrinsic radioresistance
and hypoxia [15], inactivation of PTEN may affect the
effectiveness of anticancer therapy.
These factors form the basis of an increased interest in PTEN
and other elements of the AKT pathway as the potential
prognostic and predictive markers in combined modality treat-
ment, as well as the targets for new drugs [16].
While the molecular functions of PTEN within the cell are
relatively well established, there are only a few clinical studies that
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for cancer of the head and neck. We have recently published
results of a study on molecular predictors of the effect of
accelerated (7 days a week) postoperative radiotherapy. It was
based on the analysis of loco-regional control rates obtained in a p-
CAIR (postoperative continuous accelerated irradiation) trial in
head and neck [17] relative to the expression of five molecular
markers (EGFR, Ki-67, p-53, nm23, and cyclin D) [18] and the
presence of HPV infection [19].
Methods
Objectives
The purpose of the present study is to evaluate the role of PTEN
as a prognostic and predictive factor in postoperative radiotherapy
for cancer of the head and neck. In addition, we also examine the
relationship between the expression of PTEN and markers
previously studied in this cancer type.
Clinical background of the study
The p-CAIR trial was performed between 2001 and 2004, and
recruited 279 patients with high-risk squamous cell cancer of the
larynx (158 patients) or cancer of the oral cavity/oropharynx (121
patients). Clinical characteristics of the whole group of 279
patients, a detailed presentation of the risk assessment scale,
treatment description, and the clinical outcome have been
presented elsewhere [17]. The patients were randomized to
receive 63 Gy in fractions of 1.8 Gy, given either 5 days a week
(140 patients: p-CF, postoperative conventional fractionation) or 7
days a week (139 patients: p-CAIR).
Recently, we presented analysis of the immunohistochemically
assessed expression of five molecular markers (EGFR, nm23, Ki-
67, p53 and cyclin D1) [18] and Real-Time PCR-assessed
presence of HPV infection [19] in relation to the outcome of the
trial. For the purpose of PTEN assessment, it was possible to
obtain material from 147 out of 279 patients who were originally
enrolled. The follow-up data have been updated in the present
study and show the status of the patients as of January 2010
(median follow-up time: 87 months).
We note that the update does not affect the qualitative outcome
of the analysis, because new loco-regional recurrences have not
been recorded since the last publication.
Participants
Table 1 presents clinical characteristics of 147 patients included
in the analysis. The general characteristics of the subgroup
analyzed in the present study did not differ considerably from that
of the population of 279 patients [17].
The majority of individuals participating in both arms of the
study were males (,90%). Such gender prevalence is representa-
tive for a population of HNSCC in Poland and is associated with
smoking habits and alcohol consumption.
Importantly, the risk factors for recurrence were evenly
distributed between the trial arms. The actual mean overall
radiation treatment time among 131 patients was 48.4 days
(SD=6.3) in CF vs. 35.6 (SD=6.8) in p-CAIR. Four patients in p-
CF and four in p-CAIR received total radiation doses lower than
planned, due to deteriorating general performance before or
during radiotherapy. Four patients in p-CF and three in p-CAIR
received total doses higher than in the protocol, due to local/nodal
tumor progression during treatment or treatment planning. One
patient in the p-CAIR arm died before radiotherapy was started.
The other 131 patients received 63 Gy in 1.8 Gy fractions. None
of the patients received chemotherapy. The analysis, as shown,
was performed on an intention-to-treat basis.
The analysis of PTEN expression
The PTEN expression pattern was examined immunohisto-
chemically in formalin-fixed, paraffin-embedded tumor samples
from all patients enrolled.
The monoclonal, rabbit, anti-human PTEN antibody, clone
138G6, raised against the last 100 C-terminal aminoacids of the
protein, was used in all analyses (Cell Signaling Technology,
Denver). The PTEN specificity of this antibody was confirmed
using Western blotting and immunohistochemistry techniques in
several cell lines with known PTEN status. Immunostaining was
performed according to standard guidelines: four-micrometer
sections were cut, mounted on slides, deparaffinized, and
rehydrated in xylene and in a graded series of ethanol. Epitope
retrieval was performed for 20 minutes at 98uC in TRIS buffer/
EDTA 10 mmol/l, pH 9.0. Endogenous peroxidase activity was
inactivated by 3% solution of H2O2 for 5 min. Next, primary
antibody was applied to the slides (1:100 dilution in Background
Reducing Antibody Diluent, Dako, Denmark) and incubated
overnight at 4uC. Finally, a mixture of polymer conjugated with
horseradish peroxidase and affinity-purified goat anti-rabbit Fab’
antibody fragments and DAB chromogen was used to visualize the
reaction (EnVision+ Dako, Denmark). After counterstaining in
hematoxylin, the specimens were covered with AquaMount (Dako,
Denmark) mounting medium.
Staining intensity was evaluated by a pathologist, who was
blinded to the clinical information pertaining to patients. Scoring
was performed according to a relative semi-quantification method
described originally by Perren [20] and widely used in many
recent studies concerning head and neck tumors [21], melanoma
[22], breast [3,23], ovarian [24], and colorectal [25] cancers.
Representative areas of tumor were selected and scored under
original magnification 6200. Slides were classified into two
groups, depending on the staining intensity of tumor cells in
relation to PTEN expression in adjacent normal-appearing
epithelium or stroma, which served also as an internal, positive
control. Tumors showing no staining or with staining intensity
lower than in corresponding normal tissue were classified as LOW
PTEN (Fig. 1B), while those with increased or equal expression
were considered to be HIGH PTEN (Fig. 1A).
A series of histological preparations with known PTEN status
served as positive control. Additional tumor sections, treated as
described before but without primary antibody application,
revealed no staining (negative control).
Ethics
The Ethical Committee of the Maria Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice
Branch specifically approved this study according to the national
regulations. A written, informed consent was obtained for all
participants of the study.
Statistical methods
Loco-regional failure was defined as the recurrence of cancer at
the primary tumor site, within the neck or supraclavicular nodes,
and distant metastases as the recurrence elsewhere. The survival
curves have been plotted using the Kaplan-Meier method, and
compared using the Cox f test. Taking into account the
exploratory purpose of this research and the relatively small
number of patients, the Cox f test was considered to be more
suitable for testing the differences between two groups, than was
the more commonly used log-rank test, designed for use in larger
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of importance, a univariate and multivariate Cox proportional
hazard regression analysis was performed. Only the variables that
appeared statistically significant in univariate analysis were
included in the multivariate model. The model was optimized
using a backward stepwise regression.
Results
The prognostic value of PTEN expression
Low PTEN expression was detected in 88/147 tumors (59.9%).
Among 74 patients with laryngeal cancer, 46 (62.2%) had low
expression of PTEN compared to 42/73 (57.3%) patients with cancer
of the oral cavity/oropharynx. Neither T stage (p=0.10), nor N stage
at the diagnosis (p=0.86) were related to PTEN expression, as
evaluated by the U-Mann Whitney test. PTEN expression was,
however, significantly affected by gender of the patients. Low PTEN
expression was detected in 4/15 (26.7%) females, compared to 84/
132 (63.6%) males (p=0.006, U-Mann Whitney test).
Loco-regional tumor control was highly affected by PTEN
expression: 5-year LRC was 52.3% in patients with low PTEN
expression, compared to 80.9% in patients with high PTEN
expression (p=0.0007, Fig. 2A). The prognostic significance of
PTEN was apparent both for local control (5-year LC 63.9% vs.
84.8% for low vs. high PTEN, p=0.01) and for regional (nodal)
control (5-year NC 74.6% vs. 87.9% for low vs. high PTEN,
p=0.05).
Five-year metastases-free survival was 81.4% in patients with
low PTEN expression, vs. 84.3% in patients with high PTEN
expression; the difference did not appear significant (p=0.49,
Fig. 2B). Also, the accumulated rate of metachronous tumors was
not significantly affected by PTEN expression (p=0.15, Fig. 2C).
The predictive value of PTEN expression
Because p-CAIR trial was designed to compare loco-regional
tumor control in accelerated vs. conventional postoperative
radiotherapy, it was possible to evaluate the predictive potential
of PTEN expression relative to fractionation. The clinical outcome
in a subset of 147 patients appeared representative for the outcome
observed in all 279 patients: 5-year loco-regional tumor control
was 57.6% in CF, compared to 70.6% in p-CAIR; the difference
was not statistically significant (Fig. 3A, p=0.19).
In a subgroup of 88 patients with low PTEN expression, 5-year
LRC was 47.2% in CF, compared to 56.2% in p-CAIR (Fig. 3C,
p=0.19). In a subgroup of 59 patients with high PTEN
expression, 5-year LRC was 70.8% in CF, compared to 92.7%
in p-CAIR (Fig. 3B, p=0.016). Thus, low PTEN expression was
related not only to unfavorable LRC, but also to lack of
improvement in LRC from accelerated fractionation.
PTEN versus other variables and markers
The expression of PTEN correlated neither with HPV infection,
nor with expression of any of five previously studied markers
(EGFR, nm23, Ki-67, P53, cyclin D1), as indicated by p.0.05 in
all performed U-Mann Whitney tests.
A multivariate model designed to assess an independent
prognostic significance of variables of potential importance for
LRC initially incorporated several factors, including expression of
PTEN, EGFR, nm23, Ki-67, p-53, and cyclin D1; clinical
variables such as age, gender, performance status, tumor site;
and classical pathological risk factors, such as neck node
involvement, margins, and tumor grade. HPV infection was not
incorporated into the model because only nine patients appeared
to be HPV-positive in this group, and all were locally controlled
(no uncensored data in the HPV-positive group) [19].
After we eliminated non-significant and confounding variables
from the model, only four variables appeared to be significantly
and independently related to LRC: PTEN expression (RR=2.84,
p=0.004), neck node involvement (RR=2.05, p=0.035), EGFR
expression (RR=1.91, p=0.033) and nm23 expression
(RR=1.88, p=0.041, Table 2).
Table 1. Characteristics of 147 patients with high-risk squamous cell cancer of the head and neck.
p-CF (N=73) p-CAIR (N=74) p-value
Age (median, range) 59 (39–71) 57 (41–77) 0.61
Gender F: 6 (8.2%)
M: 67 (91.8%)
F: 9 (12.2%)
M: 65 (87.8%)
0.17
T T1,T2: 20 (27.8%)
T3,T4: 53 (72.2%)
T1,T2: 17 (22.9%)
T3,T4: 57 (77.1%)
0.54
N N0: 26 (36.1%)
N+: 47 (63.9%)
N0: 18 (24.3%)
N+: 37 (75.7%)
0.73
Tumor site Oral cavity: 28 (38.4%)
Oropharynx: 9 (12.3%)
Hypopharynx/larynx: 36 (49.3%)
Oral cavity: 23 (31.1%)
Oropharynx: 12 (16.2%)
Hypopharynx/Larynx: 39 (52.7%)
0.81
Margins Neg.: 36 (49.3%)
Pos.: 26 (35.6%)
Uncertain: 11 (15.1%)
Neg.: 47 (63.5%)
Pos.: 23 (31.1%)
Uncertain: 4 (5.4%)
0.28
Grade G1: 16 (21.9%)
G2: 42 (57.5%)
G3: 15 (20.6%)
G1: 10 (13.5%)
G2: 45 (60.8%)
G3: 19 (25.7%)
0.08
HPV status Pos.: 5 (6.9%)
Neg.: 60 (82.2%)
Uncertain: 8 (10.9%)
Pos.: 4 (5.4%)
Neg.: 62 (83.8%)
Uncertain: 8 (10.8%)
0.71
p-CF: postoperative conventional fractionation.
p-CAIR: postoperative continuous accelerated fractionation.
N+: lymph node involvement.
doi:10.1371/journal.pone.0033396.t001
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PTEN as a prognostic marker
Several clinical and pathological factors have been identified to
prognose risk of recurrence after surgery for locally advanced
HNSCC [26,27]. These factors are used to select candidates for
postoperative radiotherapy and to optimize radiation dose. More
recently, based on results of large randomized clinical trials
[28,29], the patients at high risk of recurrence are considered for
postoperative radiochemotherapy. The ‘‘conventional’’ risk factors
such as positive surgical margins, invasion of more than one neck
node, extracapsular spread of nodal disease, and oral cavity/
oropharyngeal primary tumor site, except T1N0, were included
among selection criteria for a p-CAIR trial [17].
Recent advances in immunochemistry and molecular biology
have facilitated the identification of new markers that help to
prognose risk of recurrence. At least two of them (HPV infection
and EGFR expression) are progressively more recognized in a
routine clinical practice [30,31]. The results of the present study
suggest that PTEN might become another marker of major clinical
importance.
In our study we went further and tested a multivariate model,
including other potential markers (Table 2). PTEN appeared to
have a stronger prognostic value than any of the other variables
considered, including neck node involvement and EGFR expres-
sion. Only one of the variables used in a ‘‘conventional’’
evaluation of risk factors remained significant when confronted
with new markers. We could not compare the prognostic value of
PTEN and HPV infection in the present study, because lack of
uncensored data in HPV-positive group precluded such analysis.
Nevertheless, lack of correlation between PTEN expression and
HPV infection indicate that these two variables are independent.
The analysis, as shown, refer to our recently published results on
the prognostic and predictive value of five molecular markers
(EGFR, Ki-67, P53, nm23, and cyclin D) [18] and the presence of
HPV infection [19]. We had proposed a prognostic index for
recurrence after postoperative radiotherapy that incorporated
three factors of the greatest importance: expression of EGFR,
expression of nm23, and invasion of the neck nodes [18]. The
results of the present analysis and the emerging data on HPV
infection [19,30] prompt us to propose a new, improved score that
would incorporate five risk factors of foremost importance for the
outcome of postoperative radiotherapy for HNSCC:
N absence of HPV infection in tumor
N low PTEN expression
N neck node involvement
N high EGFR expression
N high nm23 expression
Figure 4 illustrates LRC in the p-CAIR trial, according to the
number of such defined risk factors. Because not all of the patients
included in the present study had established HPV status, only the
data from 123 patients with known status of all five markers were
used to plot the graph. None of the patients had zero risk factors in
the analyzed group, mostly because the prevalence of HPV
infection was low (6.9%) in this group. We expect that ongoing
research on molecular markers in cancer performed by other
investigators will help to validate and further improve this
prognostic score.
PTEN as a predictive marker
Several clinical studies demonstrated the potential of molecular
profiles to predict the benefit from accelerated radiotherapy [31–
33], including our previous report on molecular markers in the p-
CAIR trial [18].
The results of the present study indicate that the expression of
PTEN may be useful in predicting the benefit from accelerated
radiotherapy: the patients with high PTEN expression have a
favourable outcome after accelerated postoperative radiotherapy,
compared to the patients treated with conventional fractionation
and to those with low PTEN expression (Fig. 3B, C).
The clinical significance of this finding is limited by current
evidence-based prescription practice that would favour postoper-
ative radiochemotherapy over postoperative radiotherapy alone in
high-risk HNSCC [27–29]. However, the emerging data on
molecular markers and HPV infection raise several questions over
actual need of chemoradiotherapy in patients who would, likely,
have favourable outcome after postoperative radiotherapy alone.
We hope that future clinical trials and research on molecular
markers will further address this important concern.
The biological background of the present study
A possible role of PTEN loss in the pathogenesis of HNSCC has
been described by Califano [34] in his stepwise model of
carcinogenesis. Later, a whole spectrum of functional and
Figure 1. An expression of PTEN in the tumor tissue. A range of
PTEN expression in the tumor tissue: A - high, B - low. Visible positive
staining of the surrounding matrix in both specimens. Original
magnification: 1006.
doi:10.1371/journal.pone.0033396.g001
PTEN as a Prognostic Marker in HNSCC Radiotherapy
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33396structural dysfunctions of PTEN in HNSCC was demonstrated,
including mutations, losses of heterozygocity (LOH), and epige-
netic silencing [35–38]. The majority of these disorders lead to a
decrease or loss of protein expression, thus giving the rationale for
defective PTEN detection by immunohistochemistry.
Recently, a new model of PTEN role in cancer development has
been proposed and verified in vivo. According to this model, subtle
reduction (20%) in dose of PTEN, altered the biology of cancer
and the expression profiles of genes involved in a cancer cell
proliferation [39,40].
Because of the diverse expression of PTEN in normal tissues
and individual tumors, as well as the crucial role of subtle
variations of PTEN concentration for cancer phenotype develop-
ment [12], there is a need for a more sophisticated immunohis-
tochemistry scoring method. A strategy, proposed by Perren and
colleagues [20], to use normal tissue or stroma as a common
reference providing a cut-off point for normal/dysfunctional
PTEN, ensures case-to-case comparable results and was imple-
mented in our study. The same methodology was used by Lee and
co-workers [21], who investigated PTEN expression in patients
with tongue cancer and showed that loss of PTEN is connected
with shorter overall survival and event-free survival time.
Furthermore, PTEN status remained an independent predictor
of poor outcome when compared with tumor stage and nodal
status. Similarly, the significance of PTEN expression as a marker
of favourable outcome in combined modalities comprising
irradiation has been reported for many other cancers, including
astrocytomas [41], cervical [4,42] and breast cancer [20], prostate
[7,8] and colorectal cancer [43].
More ambiguous results have been shown by Tsutsui [23] and
Perez-Tonorio [3] in the context of breast cancer. They
demonstrated that prognosis more clearly depended on the
combined status of PTEN/P53 and PTEN/S-phase fraction,
respectively.
By contrast, Pattje and colleagues [44] recently showed that
there is an increased risk of locoregional failure after postoperative
radiotherapy in patients with head and neck squamous cell cancer
expressing PTEN. As a proof of concept, the authors showed a
decreased radiosensitivity in a human embryonic kidney cell line
(Hek293) with an overexpressed PTEN gene. Despite the
superficial similarities to the present studies, including tumor sites,
treatment modality or HPV infection frequency, there are many
essential differences in the experimental group and design,
between our approach and the above-mentioned research. The
present study was performed in a prospective clinical trial setting,
ensuring strictly defined criteria of patient recruitment, uniformity
Figure 2. Clinical outcome according to PTEN expression. Loco-regional control (A), distant metastases-free survival (B), and freedom from
secondary cancer (C), according to PTEN expression in 147 patients with high-risk HNSCC treated in p-CAIR trial.
doi:10.1371/journal.pone.0033396.g002
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individuals participating in both arms of the trial was heavily
skewed toward males (,90%) and correlated with tobacco
smoking, as opposed to the cited paper, where both genders were
distributed evenly.
A different methodology of immunohistochemistry scoring is
another substantial difference that could contribute to a conflicting
result. Pattje and coworkers used a less popular, absolute method
of semi-quantification [44,45], where any positive staining above
background was considered as positive. This fact is of crucial
importance in light of the new evidence, demonstrating that even a
small decrease of PTEN activity can change the biology of the
tumor and that complete loss of functionality may lead to the
opposite effects, then a subtle variation [40] in its activity. The
methodology implemented by Pattje may cause, that only cases
with complete loss of the protein expression are classified as
PTEN-dysfunctional. In the present study, a relative semi-
quantification method was utilized; thus, tumors with decreased
PTEN expression in relation to normal tissue were considered as
PTEN-dysfunctional. Such an approach seems to be consistent
with new concepts of PTEN functioning. It is also worth noting
that relative semi-quantification could be difficult to implement in
the case of the tissue matrix used in Pattje’s study, due to the scant
contents of normal tissue in TMA cores.
An interesting concept, namely ‘‘PTEN paradigm’’ or ‘‘obligate
haplo-insufficiency’’ introduced recently, may provide an addi-
tional explanation of these conflicting results. According to this
theory, PTEN cellular functions are tightly bound to P53 status. In
the case of complete PTEN loss, functional P53 directs the cell to
acute cellular senescence. Thus, heterozygous loss of PTEN is
Figure 3. PTEN expression as a predictor of benefits from p-CAIR fractionation. Loco-regional control (LRC), according to fractionation in
subset of 147 patients from the p-CAIR trial used in the present study (A), LRC according to fractionation and expression of PTEN in subset of 147
patients from the p-CAIR trial used in the present study: HIGH PTEN expression (B), LOW PTEN expression (C).
doi:10.1371/journal.pone.0033396.g003
Table 2. Factors that significantly and independently affected
LRC: results of a multivariate analysis.
Variable RR 95% CI for RR p-value
Low PTEN expression 2.84 1.38–5.80 0.004
Neck node involvement 2.05 1.04–4.00 0.035
High EGFR expression 1.91 1.05–3.48 0.033
High nm23 expression 1.88 1.09–3.65 0.041
RR: Relative Risk; CI: confidence interval.
doi:10.1371/journal.pone.0033396.t002
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wild-type P53. This pattern changes in the setting of mutated P53
cells that are unable to activate P53 do not undergo PTEN loss-
induced cellular senescence [46]. As a result, complete loss of
PTEN cooperates synergistically with partial or complete loss of
P53 [47]. Most probably, because of the high consumption of
tobacco and low proportion of HPV-positive cases (which are
mutually exclusive to P53 mutations), a prevalence of P53
mutations in the studied groups of patients was high (75.4%, as
confirmed by immunohistochemistry) [18]. In accordance with the
PTEN paradigm, synergistic effects could be expected in a case of
PTEN/P53-defective patients, leading to the favourable prognosis
in PTEN-positive individuals.
In conclusion, the results of the present study and other studies
demonstrate that the clinical usefulness of PTEN as the prognostic
or predictive marker for radiotherapy is not yet robustly defined.
Therefore, there is a clear need for new research that would
further address these interesting issues with reference to combined
treatment modalities.
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